David Simmons
President and General Manager, Established Products Business Unit

Led by David Simmons, Pfizer's Established Products Business Unit (EPBU) was created in 2008 to provide underserved patients with affordable medicines characterized by Pfizer's reputation for quality, safety, and innovation. Much of the business unit's success is due to its entrepreneurial culture which is characterized by a fast, flexible and focused pursuit of profitable growth opportunities.

Established products are medicines that have lost or are close to losing their exclusivity. Pfizer has over 500 established products - including many familiar brands such as Norvasc, Zoloft, and Zithromax. Pfizer's established products include solid oral dose medications, sterile injectables, and orphan therapeutic products.

David helped create and lead the implementation of Pfizer's established products strategy. In 2009, under David's leadership, EPBU broke new ground for the company by in-licensing more than 100 molecules from partner companies.

In addition to its revenue growth, the EPBU is uniquely positioned to help Pfizer meet its commitment to set the standard for quality, safety and value of medicines. In an industry that too often suffers from quality and supply issues, Pfizer's strong reputation for product integrity and reliability sets it apart from the competition.

David Simmons brings 12 years of international Pfizer experience - including executive responsibilities in the United Kingdom, Greece, Canada and the United States - and nine years of experience in the steel industry to his role as President and General Manager of the EPBU. He serves as the Executive Sponsor of the Pfizer African American Leadership Network and as a member of the U.S.-India Business Council.